Can gout turn into rheumatoid arthritis?

No. Gout and rheumatoid arthritis are completely different diseases with different causes. Gout is caused by uric acid crystal deposition in joints, while RA is an autoimmune disease where the immune system attacks the joint lining. However, they can co-exist, and both cause joint pain, swelling, and stiffness. A rheumatologist can distinguish them through blood tests (RF, anti-CCP for RA; uric acid for gout) and joint fluid analysis.

Why does gout have fewer drug trials than RA?

Gout has historically been under-researched compared to RA. RA drug development has been revolutionised by biologics, creating a large trial infrastructure. Gout research is expanding rapidly, especially with new urate-lowering therapies and anti-inflammatory agents for flares. The UK has several active gout trials, and the field is growing.

What new gout treatments are being tested?

Emerging gout treatments include new xanthine oxidase inhibitors (topiroxostat), uricosuric agents (lesinurad, dotinurad), recombinant uricase (pegloticase biosimilars), anti-IL-1β agents for flare prevention (canakinumab), and combination urate-lowering therapies. Several of these are in UK trials.

Rheumatology Comparison Updated 27 May 2026

Gout vs Rheumatoid Arthritis — Clinical Trial Comparison

🔥

Gout

Uric acid crystal joint inflammation

🦴

Rheumatoid Arthritis

Autoimmune joint destruction

Gout and rheumatoid arthritis (RA) are two of the most common inflammatory joint diseases in the UK. Despite both causing joint pain and swelling, they have entirely different causes — gout is driven by uric acid crystal deposition while RA is an autoimmune attack on joint linings. Their trial landscapes differ dramatically, with RA benefiting from decades of biologic drug development while gout trials are a rapidly growing field.

Key Differences at a Glance

Feature	Gout	Rheumatoid Arthritis
Cause	Uric acid crystal deposition in joints and soft tissues	Autoimmune synovial inflammation (anti-CCP and RF positive in most)
UK prevalence	~2.5% of adults (~1.5 million)	~1% of adults (~600,000)
Typical onset	Men 30–50, women post-menopause; often acute attacks	30–60; insidious onset, more common in women (3:1)
Key joints affected	First metatarsophalangeal (big toe), ankles, knees	Hands (MCP, PIP), wrists, feet — symmetrical
Pattern	Acute attacks with pain-free intervals; can become chronic	Chronic progressive disease with flares
Key biomarkers	Serum urate, joint fluid crystals, dual-energy CT	RF, anti-CCP, CRP/ESR, ultrasound/MRI synovitis

Clinical Trial Availability

Trial Aspect	Gout	Rheumatoid Arthritis
UK trials actively recruiting	10–20 studies	50–80 studies
Most common trial phase	Phase 2–3	Phase 2–4
Top interventions tested	New urate-lowering therapies, anti-IL-1β agents, flare prevention, pegloticase biosimilars	Next-gen biologics, JAK inhibitors, biosimilars, CAR-T cell therapy, precision medicine
Biological treatments	Emerging (canakinumab for flares, IL-1 targeting)	Established and extensive (TNF inhibitors, IL-6, B-cell depletion, T-cell co-stimulation blockade)
Prevention trials	Urate-lowering optimisation, diet and lifestyle	Treat-to-target strategies, early intervention, remission induction
Biosimilar trials	Limited	Major category (multiple biosimilar TNF inhibitors)

Exciting Emerging Treatments

Gout Trials

Dotinurad (selective URAT1 inhibitor) — next-generation uricosuric agent
Pegloticase biosimilars and new formulations — for refractory gout with tophi
Anti-IL-1β (canakinumab) for flare prevention — targeted anti-inflammatory
Combination urate-lowering therapy — xanthine oxidase inhibitors + uricosurics
Diet and microbiome interventions — novel approaches to uric acid management
Precision dosing of allopurinol — pharmacogenomics-guided (HLA-B*58:01 testing)

Rheumatoid Arthritis Trials

CAR-T cell therapy — engineered immune cells targeting autoimmune B-cells (early trials very promising)
Next-generation JAK inhibitors — improved selectivity and safety profiles
Precision medicine approaches — genetic and biomarker-guided treatment selection
Biosimilar switching studies — real-world evidence for cost-effective biologics
Treat-to-target digital tools — AI-guided disease activity monitoring
Oral tolerance induction — retraining the immune system via oral autoantigens

💡 Gout is the most treatable form of arthritis — but most patients aren't controlled

Despite effective urate-lowering therapy (allopurinol, febuxostat), only about 40% of UK gout patients reach target urate levels. Clinical trials are testing better dosing strategies, combination therapies, and patient education approaches. If your gout isn't well-controlled, trial participation could give you access to next-generation urate-lowering treatments and specialist monitoring.

Eligibility Differences

Gout Trial Criteria

Confirmed gout diagnosis (crystal identification or clinical criteria)
Serum urate level thresholds (typically ≥ 0.36 mmol/L despite treatment for refractory trials)
Flare frequency requirements for flare prevention trials (≥ 2 per year typical)
Tophus presence/absence — some trials specifically target tophaceous gout
Renal function thresholds (eGFR) — important for urate-lowering drug trials

Rheumatoid Arthritis Trial Criteria

2010 ACR/EULAR classification criteria — confirmed RA diagnosis
Disease activity scores (DAS28, CDAI, SDAI) — moderate-to-severe for biologic trials
Seropositivity (RF and/or anti-CCP) — some trials require, others accept seronegative
Failed conventional DMARDs (methotrexate) — most biologic trials require prior failure
Duration of disease — early RA trials (<2 years) vs established RA trials

🔥 Gout Trials

Find actively recruiting gout clinical trials across the UK

View Gout Trials

🦴 RA Trials

Find actively recruiting rheumatoid arthritis clinical trials across the UK

View RA Trials